DDInter1340 DDInter178
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Omeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Omeprazole {u} (Compound) treats {v} (Disease) Barrett's esophagus
Omeprazole {u} (Compound) binds {v} (Gene) CYP1A2
Omeprazole {u} (Compound) upregulates {v} (Gene) TIPARP
Omeprazole {u} (Compound) palliates {v} (Disease) systemic scleroderma
Omeprazole {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C19 Inhibitors
Omeprazole {u} (Compound) downregulates {v} (Gene) THAP11
Omeprazole {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Omeprazole (Compound) resembles Pantoprazole (Compound)
Omeprazole (Compound) resembles Esomeprazole (Compound)
Omeprazole (Compound) treats Barrett's esophagus (Disease)
Omeprazole (Compound) binds CYP1A2 (Gene)
Omeprazole (Compound) upregulates TIPARP (Gene)
Omeprazole (Compound) palliates systemic scleroderma (Disease)
Omeprazole (Compound) is included by Cytochrome P450 2C19 Inhibitors (Pharmacologic Class)
Omeprazole (Compound) downregulates THAP11 (Gene)
Omeprazole (Compound) causes Alanine aminotransferase increased (Side Effect)